You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm's head of strategy said now that it is a public company and paying down debt, Ortho can consider acquisitions that had been out of its reach.
Mina said that most of the diagnostic testing completed so far during the pandemic has done little to curb the spread of the coronavirus.
According to one of the test developers, its technology has the potential to enable the manufacturing of tests where they are needed in low-resource settings.
The firm's CEO said that the deprioritization of its submission for a standalone SARS-CoV-2 assay running on its Verigene I molecular diagnostic instrument is puzzling.
With new platforms in its plans, Accelerate will target hospitals that have a bacterial identification method but want to add rapid susceptibility testing.
The firm anticipates completing the study in about 18 months and then applying for US Food and Drug Administration clearance for its multimodal platform and assays.
Molzym said a new analytic platform, called AutoSepT, would enable fast pathogen identification directly from specimens in less than five hours.
Hologic said the acquisition of Biotheranostics will give it a company that operates in markets that are adjacent and complementary to its own.
The firm said that a US FDA clearance would broaden the adoption of its growing portfolio of diagnostic assays for Alzheimer's disease.
Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.